Search for: "T. G., II" Results 161 - 180 of 2,341
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Nov 2023, 1:28 am by Rose Hughes
According to the Enlarged Board of Appeal in G 1/03 and G 1/16, a disclaimer not mentioned in the application as filed may be added to the claim in order to restore novelty in view of an accidental anticipation by prior art. [read post]
25 Mar 2020, 11:52 am by Dennis Crouch
An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μg/ml and a maximum of 1.0 μg/ml, the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline; (ii) a delayed release (DR) portion comprising 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients. [read post]
30 Mar 2015, 8:04 am
Part II Forum: The Baka Case Mart Susi, The Baka Case – The Unbearable Price of Individual Justice Gábor Kártyás, The Labour Lawyer’s Reading of the Baka Case Part III Developments in International Law Dinah Shelton, The Benefits and Limitations of a Human Rights Approach to Environmental Protection László Blutman, Law in Mind: Towards an Explanatory Framework for Customary International Law László Burián,… [read post]
25 Feb 2012, 11:01 am by Oliver G. Randl
Furthermore, the notice contained the following statement: “All cases affected by decision T 39/03 will henceforth be stayed only where the two abovementioned conditions are fulfilled. [read post]
13 Oct 2019, 5:03 am
  Whilst the President’s referral is pending, the guidance that Rule 28(2) EPC excludes products produced by essentially biological processes from patentability remains unchanged in the 2019 guidelines (G-II.5.4). [read post]
20 Feb 2010, 11:01 am by Oliver G. Randl
Three questions had been referred to the Enlarged Board by interlocutory decision T 1319/04.The claim that triggered the question read as follows:1. [read post]
5 Jul 2019, 5:00 am by Aron Laszlo
On appeal, the Metropolitan Court of Appeal (Fővárosi Ítélőtábla) set aside the ground for refusal concerning the technical function but upheld the refusal for all goods on the basis of the substantial value. [read post]
28 Jun 2017, 7:31 pm by FDABlog HPM
The statute (FDC Act 744B(g)(5)) would also be amended to include certain penalties for failure to pay the new ANDA Holder Program Fee: (A) IN GENERAL. [read post]
17 Apr 2019, 7:28 am by Jessica Kroeze
By letter of 17 January 2019, the appellant filed the following new item of evidence:D36: Response by Mr M van Gardingen dated 17 January 2019 to the legal opinions of Mr G Kuipers and Prof. [read post]
17 Nov 2010, 3:01 pm by Oliver G. Randl
The conditions set out by the decision G 4/95 are applicable to any accompanying person. [read post]
27 Aug 2013, 5:01 pm by oliver randl
A disclaimer may be allowable if it inter alia serves to re-establish novelty by distinguishing a claim over a prior art document under A 54(3), but it must meet the requirements of clarity and conciseness of A 84  (see G 1/03 [headnotes II.1 and II.4]). [read post]
14 Apr 2011, 3:01 pm by Oliver G. Randl
Following decisions G 1/03 and G 2/03 [headnote II.1], such disclaimers are allowed even when not disclosed. [read post]
22 Oct 2012, 5:01 pm by oliver randl
The standard to be applied in deciding whether the claimed priority date is to be acknowledged is whether this subject-matter is directly and unambiguously derivable from the priority document D28 as a whole (see decision G 2/98 [headnote]). [read post]